Secondary Cancer Rates Following Breast Cancer Diagnosis
|
|
- Jessie Shields
- 7 years ago
- Views:
Transcription
1 Copyright E 2007 Journal of Insurance Medicine J Insur Med 2007;39: ORIGINAL RESEARCH Secondary Cancer Rates Following Breast Cancer Diagnosis David Wesley, MD Life table analysis and other mortality methods apply well to end points other than mortality. This paper demonstrates the application of mortality experience methodology to the recurrence of breast cancer and/or new primaries in women previously diagnosed with primary breast cancer. Specific recurrence rates are broken out by duration as well as attributes available at the time of primary breast cancer diagnosis: stage, histology, age band, and year of diagnosis. Use of attained age is demonstrated to control for the effect of aging over long durations. Breast cancer recurrence is shown to drop to a relatively low rate compared with the rate of new primary occurrence. Address: Transamerica Reinsurance, 401 North Tryon Street, Suite 700, Charlotte, NC 28202; ph: ; fax: ; david.wesley. md@transamerica.com. Correspondent: David Wesley, MD, Vice President, Medical Research & Development. Key words: Breast cancer, SEER, cancer recurrence, mortality methodology. Received: January 10, 2007 Accepted: March 13, 2007 INTRODUCTION Breast cancer is a common cancer in women worldwide. In the United States, it is estimated that 1 in 8 women will develop breast cancer during their lifetime. Breast cancer is the leading cause of death in American women aged 40 to 55, and it was only recently surpassed by lung cancer as the leading cause of cancer deaths at all ages. See Richie and Swanson for an excellent literature review. 1 Breast cancer is also known for relapsing disease; local, regional, and/or distant relapse of the index tumor is common, as is the recurrence of a second breast primary. Women with breast cancer histories are also at risk of developing primary cancers originating from other organs. Breast cancer treatment is expensive, and the medical cost of recurrent disease is often greater than that of the original treatment. The Surveillance Epidemiology and End- Results (SEER) is a program managed by the National Cancer Institute (NCI). SEER data has been collected since 1973 from 7 founding cancer registries in SF-Oakland; Connecticut; Detroit; Hawaii; Iowa; New Mexico and Utah. Seattle was added in 1974 and Atlanta in More recent additions were in 1992 (Alaska, San Jose, Los Angeles and rural Georgia) and 2000 (greater California, Kentucky, Louisiana and New Jersey). The data includes de-identified but otherwise seriatim data with details about newly diagnosed cancer cases and follow-up infor- 98
2 WESLEY BREAST CANCER Table 1. Age Distribution of Observations ( ) Age Band Count Percent Cum % % 0.08% % 0.68% % 2.71% , % 7.30% , % 15.4% , % 26.2% , % 37.6% , % 49.2% , % 61.1% , % 73.1% , % 84.3% , % 93.8% , % 100% Total 357, % mation including date and cause of death. This data is available to qualified researchers in the form of re-coded public use data files. I was recently asked by my Japanese colleagues to provide summary data from the US Surveillance Epidemiology and End- Results (SEER) database that could be used to price a medical cover for the Japan market. The proposed product would cover women with a history of breast cancer, who have no evidence of disease (NED) at the time of underwriting. The coverage would pay for medical expenses incurred upon the development of any form of secondary cancer: recurrence (second breast primary) or new cancer. For pricing, one needs to know the annual rate of failures (secondary cancers), not simply the proportion of patients that would eventually fail. My initial reaction was that it could not be done. There are no fields in the SEER tables that flag recurrences, new tumors, or even the achievement of NED status. Also, to my knowledge, no such study has been reported in the insurance medicine literature. Upon further review, it was determined that a satisfactory study could be done. Furthermore, it is possible to provide summary data to pricing colleagues in a format that does not compromise SEER rules for public-use data. The summary data can be viewed in a variety of ways using pivot-table or crosstabulation technology. This paper highlights both the methodology and a few of the initial insights that it has provided. METHODS NCI provides a statistical software package named SEER-Stat for analyzing SEER data. SEER-Stat has grown from an in-house NCI tool with a quirky user interface to an easy-to-use program with a sophisticated interface. One of the SEER-Stat features that is attractive to medical directors is the ability to perform life table analysis that includes comparative mortality based on appropriate population mortality tables. The vast majority of analyses performed by medical directors are based on this tool. Unfortunately, SEER-Stat does not allow for the study of recurrence rates, so a professional statistics software package, Stata 9, was needed to restructure the data in the SEER public-use ASCII files. 2,3 Evaluation of the 86 fields provided in the public-use data allowed selection of observations with the following characteristics: N Sex 5 female N Age at diagnosis $20,,85 N Initial breast cancer diagnosis is first primary, both within and outside of SEER database N Initial diagnosis made in 1979 or later N Initial tumor shows invasive behavior N No concomitant tumor of any other organ system N Time to failure greater than 0 months N Did not die of breast cancer within first year of diagnosis Patient ID numbers are frequently duplicated between the 17 different SEER registries, but never within the same site. Thus, a combination of site ID and patient ID provides a unique identifier. Each cancer diagnosis for a given patient is assigned 99
3 Table 2. Surgical and Radiation Treatments ( ) Surgery Radiation Treatment None Ext Beam Other Rad Unknown Total Biopsy Lumpectomy 16,326 53, ,756 Modified Radical 105,986 13, ,972 Radical Other 25, ,517 Unknown 53,250 58, ,293 Total 207, ,846 14, ,091 a sequence number. Through analysis of these sequence numbers and other flags, one is able to identify secondary as well as primary cancer diagnoses. Time to failure is simply the difference between the time of diagnosis for the secondary cancer and that for the primary. Failure for this study was defined as a secondary cancer of any type: recurrent breast (second primary) or primary of any other tissue. In addition to failure, on-study exposure to risk ended for any of the following conditions: end of study (December 31, 2003), death (any cause), and lost to follow-up. Additionally, follow-up for this study was limited to the first 20 durations (yearly intervals after diagnosis). The finest unit of time available in the SEER ASCII files is the month; used for both time of diagnosis and end of study. Months of on-study exposure to risk were calculated for each observation, and the defined failures were flagged. The attributes of interest in this study (age band, year of diagnosis, histologic type, stage, surgery type, radiation therapy) were retained for each observation. Individual exposures were then sub-divided by duration (interval year after diagnosis) and calendar year of exposure. Exposures, and failures where applicable, were then summed over observations with the same attributes and a new, fully de-identified database was formed. These summary rec- Table 3. Histologic Type Distribution by Stage ( ) Histology SEER Stage A Localized Regional Distant Unknown Total Intraductal 156,397 88, ,761 Lobular 15, ,315 Mixed 13, ,062 Adenocarcinoma Mucinous Comedo Medullary Tubular Paget s Inflammatory Papillary Adenocystic NOS Total 216, ,985 15, ,
4 WESLEY BREAST CANCER Failure rates by duration (annual intervals after diagnosis). ords lend themselves to rapid pivot-table analysis. The stage attribute is based on historic SEER Stage A, as defined in the SEER User File Documentation. It is produced by collapsing all available extent of disease information into the following categories: N Localized An invasive neoplasm confined entirely to the organ of origin. N Regional A neoplasm that has extended beyond the limits of the organ of origin directly into surrounding organs or tissues; into regional lymph nodes by way of the lymphatic system; or by a combination of extension and regional lymph nodes. N Distant A neoplasm that has spread to parts of the body remote from the primary tumor either by direct extension or by discontinuous metastasis to distant organs, issues, or via the lymphatic system to distant lymph nodes. Histologic types are also defined in the SEER documentation and in ICD-O-2. Surgery and radio-therapy categories are defined in the SEER User File Documentation. Confidence intervals were calculated using the binomial distribution when the count of failures exceeded 100, and using the exact Poisson distribution otherwise. RESULTS There were 357,091 patients who qualified under the constraints detailed in Methods. Their average age was 59.9 years, and they were all females. For this group, there were 39,236 failures experienced during 2,417,694 person-years of exposure. Thus, the average follow-up was 6.8 years and the average failure rate was 16.2 per 1000 person-years. Tables 1-3 give further details about the study group. In Tables 4 9, all failure rates are in units of 1/1000 person-years. All confidence intervals are 95%. The trends in Table 4 can be best appreciated if displayed graphically. Figure 1 shows the occurrence rates for both Table 4. Failure Rates by (Annual Intervals after Diagnosis) All Failures Breast CA only Other Cancers rate 95% CI Failures rate 95% CI Failures rate 95% CI Failures , , ,
5 Table 5a. Failure rates by Stage and All Failure Types Stage Localized Regional Distant Unknown breast cancer and all other cancers during each of the first 20 durations after diagnosis with primary breast cancer. In Tables 5 9, exposure and failures are broken out by a variety of attributes of interest and the corresponding rates (per 1000 personyears) are calculated for each category. DISCUSSION The restructured database from which Tables 4 9 are derived contains 828,414 records many more than the number of women in the study. At the same time, each record is a summary of exposure contributions from many different women. This seeming paradox is due to the restructured data representing slices of exposure, which are further split according to the various attributes of interest. The data fields for each record are: failure type, year of diagnosis, age band, histology, stage, surgery, radiation, year of exposure, attained age at exposure, duration of exposure, person-years of exposure, and number of failures. Most of these records (795,479) had no failures; 28,280 had a single failure; 3519 had 2 failures; and so on down to 2 records with 10 failures. At their atomic level, these individual records are fairly meaningless. Significance comes from summation over a small number of higher-level attributes as shown in the results section. The tables shown are only a few of the possible ways to analyze this particular restructuring of the SEER data. Not only are there many other possible analyses of this database, other databases can be formed from the SEER data based on other attributes of breast cancer cases, as well as databases for other cancers. By choosing a different end-point, this methodology applies to mortality study as well. In fact, the methods are derived from those used by life insurers to report their Table 5b. Failure Rates by Stage and Breast Cancer Failures Stage Localized Regional Distant Unknown
6 WESLEY BREAST CANCER Table 5c. Failure Rates by Stage and Non-Breast Cancer Failures Stage Localized Regional Distant Unknown Table 6a. Failure Rates by Year of Diagnosis and All Failure Types Year of diagnosis mortality experience. What is truly unique to this study is the demonstration that secondary cancers can be identified within the SEER data and time to failure for this end-point can be studied in the same way as mortality. We have been taught that breast cancer has a long tail with significant excess mortality occurring as many as 15 years post diagnosis. Review of Table 4 shows that after the first year, breast cancer recurrence rates drop Table 6b. Failure Rates by Year of Diagnosis and Breast Cancer Recurrences Only Year of diagnosis
7 Table 7. Failure Rates by Histology and All Failure Types Histology Intraductal Lobular Mixed Adenocarcinoma Mucinous Comedo Medullary Tubular Paget s Inflammatory Adenocystic NOS
8 WESLEY BREAST CANCER Table 8. Failure Rates by Age at Diagnosis and All Failure Types Age
9 Table 9. Failure Rates by Attained Age at Time of Exposure and All Failure Types Attained Age to a stable level lower than that for developing new primaries in other organs. Further study of long-term breast cancer mortality is indicated. While the rate of all secondary cancers appears to increase with duration post diagnosis (Tables 4, 5b and 6b), there is something else occurring. These patients are growing older, and significantly so by durations 15 or 20. Note the second through fifth intervals in Table 8. It is clear that the rate of secondary cancers is greater at older ages. A way to counter this aging effect and isolate the durational significance is to use attained age as in Table 9. This table shows that after the first year, there is no significant change in secondary cancer rates over the following durations. Further study is under way that will apply these analytic methods to mortality in breast cancer, as well as relapsed disease and mortality in other cancers. REFERENCES 1. Richie RC, Swanson JO. Breast Cancer: A Review of the Literature. J Insur Med. 2003;35: StataCorp LP. College Station, TX, Available at: 3. Surveillance, Epidemiology, and End Results (SEER) Program. Public-Use Data ( ), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. Available at: Released on: April
Secondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer
Copyright E 2007 Journal of Insurance Medicine J Insur Med 2007;39:242 250 MORTALITY Secondary Cancer and Relapse Rates Following Radical Prostatectomy for Prostate-Confined Cancer David Wesley, MD; Hugh
More informationLikelihood of Cancer
Suggested Grade Levels: 9 and up Likelihood of Cancer Possible Subject Area(s): Social Studies, Health, and Science Math Skills: reading and interpreting pie charts; calculating and understanding percentages
More informationNational Cancer Institute
National Cancer Institute Information Systems, Technology, and Dissemination in the SEER Program U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Information Systems, Technology,
More informationChapter 14 Cancer of the Cervix Uteri
Carol L. Kosary Introduction Despite the existence of effective screening through the use of Pap smears since the 195 s, there were 9,71 estimated cases of invasive cervical cancer and 3,7 deaths in 26
More informationTable 16a Multiple Myeloma Average Annual Number of Cancer Cases and Age-Adjusted Incidence Rates* for 2002-2006
Multiple Myeloma Figure 16 Definition: Multiple myeloma forms in plasma cells that are normally found in the bone marrow. 1 The plasma cells grow out of control and form tumors (plasmacytoma) or crowd
More informationWisconsin Cancer Data Bulletin Wisconsin Department of Health Services Division of Public Health Office of Health Informatics
Wisconsin Cancer Data Bulletin Wisconsin Department of Health Services Division of Public Health Office of Health Informatics In Situ Breast Cancer in Wisconsin INTRODUCTION This bulletin provides information
More informationUnderstanding your pathology report
Understanding your pathology report 2 Contents Contents Introduction 3 What is a pathology report? 3 Waiting for your results 4 What s in a pathology report? 4 Information about your breast cancer 5 What
More informationTheories on Metastasis: Innovative Thinking An Advocacy Perspective
Theories on Metastasis: Innovative Thinking An Advocacy Perspective Project LEAD Workshop NBCC Annual Advocacy Conference 2011 Musa Mayer AdvancedBC.org 1 The Big Question If we want to end death from
More informationKomorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
More informationNEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA)
NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) Merat Esfahani, MD Medical Oncologist, Hematologist Cancer Liaison Physician SwedishAmerican Regional Cancer Center
More informationMunich Cancer Registry
Munich Cancer Registry Baseline statistics Selection Matrix Homepage Deutsch Munich Cancer Registry at Munich Cancer Center Marchioninistr. 15 Munich, 81377 Germany http://www.tumorregister-muenchen.de/en
More informationMunich Cancer Registry
Munich Cancer Registry Baseline statistics Selection Matrix Homepage Deutsch Munich Cancer Registry at Munich Cancer Center Marchioninistr. 15 Munich, 81377 Germany http://www.tumorregister-muenchen.de/en
More informationOvarian Cancer. in Georgia, 1999-2003. Georgia Department of Human Resources Division of Public Health
Ovarian Cancer in Georgia, 1999-23 Georgia Department of Human Resources Division of Public Health Acknowledgments Georgia Department of Human Resources......B. J. Walker, Commissioner Division of Public
More informationKidney Cancer OVERVIEW
Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney
More informationMunich Cancer Registry
Munich Cancer Registry Baseline statistics Selection Matrix Homepage Deutsch Munich Cancer Registry at Munich Cancer Center Marchioninistr. 15 Munich, 81377 Germany http://www.tumorregister-muenchen.de/en
More informationEffect of Risk and Prognosis Factors on Breast Cancer Survival: Study of a Large Dataset with a Long Term Follow-up
Georgia State University ScholarWorks @ Georgia State University Mathematics Theses Department of Mathematics and Statistics 7-28-2012 Effect of Risk and Prognosis Factors on Breast Cancer Survival: Study
More informationIn The Abstract A quarterly newsletter from the
In The Abstract A quarterly newsletter from the Kentucky Cancer Registry Large Hospital Edition July, 2000 KCR FALL WORKSHOP Sept. 14-16, 2000 Enclosed with this newsletter is a packet of information containing
More informationDictionary of SEER*Stat Variables November 2011 Submission (released April 2012) http://seer.cancer.gov/data/seerstat/nov2011/ 1 of 18
November 2011 Data Submission Item # refers to the item - see http://www.naaccr.org/standardsandregistryoperations/volumeii.aspx CS= Collaborative Staging SSF = Site-specific Factor Field Item # Description
More informationProstate Cancer. Racial Differences in Prostate Cancer Treatment Outcomes. Prostate Cancer Epidemiology. Prostate Cancer Epidemiology
Prostate Cancer Anatomy Paul A. Godley, MD, PhD Cancer Incidence, Males Prostate Cancer Epidemiology 24 Estimated New Cancer Cases Melanoma 29,9 Oral 18,55 Stomach 13,4 Leukemias 19,2 Kidney 22,8 Lymphomas
More informationBreast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis?
Breast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis? Erin I. Lewis, BUSM 2010 Cheri Nguyen, BUSM 2008 Priscilla Slanetz, M.D., MPH Al Ozonoff, Ph.d.
More informationGeneral Rules SEER Summary Stage 2000. Objectives. What is Staging? 5/8/2014
General Rules SEER Summary Stage 2000 Linda Mulvihill Public Health Advisor NCRA Annual Meeting May 2014 National Center for Chronic Disease Prevention and Health Promotion Division of Cancer Prevention
More informationProstate Cancer. Treatments as unique as you are
Prostate Cancer Treatments as unique as you are UCLA Prostate Cancer Program Prostate cancer is the second most common cancer among men. The UCLA Prostate Cancer Program brings together the elements essential
More informationDespite the broad advances made in cancer research and interventions
7th Biennial Symposium on Minorities, the Medically Underserved and Cancer Supplement to Cancer 199 The Unequal Cancer Burden Efforts of the Centers for Disease Control and Prevention to Bridge the Gap
More informationCASE COMPLETENESS AND DATA QUALITY ASSESSMENTS IN CENTRAL CANCER REGISTRIES AND THEIR RELEVANCE TO CANCER CONTROL
CASE COMPLETENESS AND DATA QUALITY ASSESSMENTS IN CENTRAL CANCER REGISTRIES AND THEIR RELEVANCE TO CANCER CONTROL Steven D. Roffers, PA, CTR "The great society is a place where (people) are more concerned
More informationEarly Prostate Cancer: Questions and Answers. Key Points
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Early Prostate Cancer:
More informationEarly mortality rate (EMR) in Acute Myeloid Leukemia (AML)
Early mortality rate (EMR) in Acute Myeloid Leukemia (AML) George Yaghmour, MD Hematology Oncology Fellow PGY5 UTHSC/West cancer Center, Memphis, TN May,1st,2015 Off-Label Use Disclosure(s) I do not intend
More informationEndometrial Cancer Treatment
Endometrial Cancer Treatment January 2006 By Shelly Smits, RHIT, CCS, CTR mary by Ian Thompson, MD Data Source: Cancer registry information on uterine cancer diagnosed 1/1/2000 to 12/31/2004. Reason for
More informationChapter I Overview Chapter Contents
Chapter I Overview Chapter Contents Table Number Contents I-1 Estimated New Cancer Cases and Deaths for 2005 I-2 53-Year Trends in US Cancer Death Rates I-3 Summary of Changes in Cancer Incidence and Mortality
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationManagement of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs. Case Study. Surgery. Lumpectomy and Radiation
Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs Michael Alvarado, MD Associate Professor of Surgery University of California San Francisco Case Study 59 yo woman with new palpable
More informationMeasures of Prognosis. Sukon Kanchanaraksa, PhD Johns Hopkins University
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationDisparities in Stage at Diagnosis, Survival, and Quality of Cancer Care in California by Source of Health Insurance
Disparities in Stage at Diagnosis, Survival, and Quality of Cancer Care in California by Source of Health Insurance Acknowledgements and Disclaimer The collection of cancer incidence data used in this
More informationGuide to Understanding Breast Cancer
An estimated 220,000 women in the United States are diagnosed with breast cancer each year, and one in eight will be diagnosed during their lifetime. While breast cancer is a serious disease, most patients
More informationGENERAL CODING. When you review old cases that were coded to unknown, make corrections based on guidelines in effect at the time of diagnosis.
GENERAL CODING When you review old cases that were coded to unknown, make corrections based on guidelines in effect at the time of diagnosis. Exception: You must review and revise EOD coding for prostate
More information2010 SITE REPORT St. Joseph Hospital PROSTATE CANCER
2010 SITE REPORT St. Joseph Hospital PROSTATE CANCER Humboldt County is located on the Redwood Coast of Northern California. U.S census data for 2010 reports county population at 134,623, an increase of
More informationSeton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50
General Data Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50 The vast majority of the patients in this study were diagnosed
More informationOncology Annual Report: Prostate Cancer 2005 Update By: John Konefal, MD, Radiation Oncology
Oncology Annual Report: Prostate Cancer 25 Update By: John Konefal, MD, Radiation Oncology Prostate cancer is the most common cancer in men, with 232,9 new cases projected to be diagnosed in the U.S. in
More informationCarcinoma of the Cervix. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology
Carcinoma of the Cervix Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology Cervical Cancer Treatment Treatment Microinvasive (Stage IA1): Simple (extrafascial) hysterectomy/cone
More informationMetastatic Cervical Cancer s/p Radiation Therapy, Radical Hysterectomy and Attempted Modified Internal Hemipelvectomy
Metastatic Cervical Cancer s/p Radiation Therapy, Radical Hysterectomy and Attempted Modified Internal Hemipelvectomy Sarah Hutto,, MSIV Marc Underhill, M.D. January 27, 2009 Past History 45 yo female
More informationThe Ontario Cancer Registry moves to the 21 st Century
The Ontario Cancer Registry moves to the 21 st Century Rebuilding the OCR Public Health Ontario Grand Rounds Oct. 14, 2014 Diane Nishri, MSc Mary Jane King, MPH, CTR Outline 1. What is the Ontario Cancer
More informationHAVE YOU BEEN NEWLY DIAGNOSED with DCIS?
HAVE YOU BEEN NEWLY DIAGNOSED with DCIS? Jen D. Mother and volunteer. Diagnosed with DCIS breast cancer in 2012. An educational guide prepared by Genomic Health This guide is designed to educate women
More informationTable of Contents. Acknowledgments. Executive Summary. Chapter 1: Introduction. Chapter 2: Cancer Incidence
Table of Contents Table of Contents Acknowledgments Acronyms Executive Summary Chapter 1: Introduction Chapter 2: Cancer Incidence Section I. Cancer Incidence Section II. Stage at Diagnosis Chapter 3:
More informationSingapore Cancer Registry Annual Registry Report Trends in Cancer Incidence in Singapore 2009 2013. National Registry of Diseases Office (NRDO)
Singapore Cancer Registry Annual Registry Report Trends in Cancer Incidence in Singapore 2009 2013 National Registry of Diseases Office (NRDO) Released November 3, 2014 Acknowledgement This report was
More informationSPECIAL ARTICLE SUBJECTS AND METHODS
SPECIAL ARTICLE Annual Report to the Nation on the Status of Cancer, 1975, Featuring the Uses of Surveillance Data for Cancer Prevention and Control Hannah K. Weir, Michael J. Thun, Benjamin F. Hankey,
More informationBreast Cancer: from bedside and grossing room to diagnoses and beyond. Adriana Corben, M.D.
Breast Cancer: from bedside and grossing room to diagnoses and beyond Adriana Corben, M.D. About breast anatomy Breasts are special organs that develop in women during puberty when female hormones are
More informationductal carcinoma in situ (DCIS)
Understanding ductal carcinoma in situ (DCIS) and deciding about treatment Understanding ductal carcinoma in situ (DCIS) and deciding about treatment Developed by National Breast and Ovarian Cancer Centre
More informationUnderstanding ductal carcinoma in situ (DCIS) and deciding about treatment
Understanding ductal carcinoma in situ (DCIS) and deciding about treatment Developed by National Breast and Ovarian Cancer Centre Funded by the Australian Government Department of Health and Ageing Understanding
More informationEpidemiology, Staging and Treatment of Lung Cancer. Mark A. Socinski, MD
Epidemiology, Staging and Treatment of Lung Cancer Mark A. Socinski, MD Associate Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive Cancer Center University of
More informationBreast Imaging Made Brief and Simple. Jane Clayton MD Associate Professor Department of Radiology LSUHSC New Orleans, LA
Breast Imaging Made Brief and Simple Jane Clayton MD Associate Professor Department of Radiology LSUHSC New Orleans, LA What women are referred for breast imaging? Two groups of women are referred for
More informationColorectal cancer. A guide for journalists on colorectal cancer and its treatment
Colorectal cancer A guide for journalists on colorectal cancer and its treatment Contents Contents 2 3 Section 1: Colorectal cancer 4 i. What is colorectal cancer? 4 ii. Causes and risk factors 4 iii.
More informationAnalysis of Population Cancer Risk Factors in National Information System SVOD
Analysis of Population Cancer Risk Factors in National Information System SVOD Mužík J. 1, Dušek L. 1,2, Pavliš P. 1, Koptíková J. 1, Žaloudík J. 3, Vyzula R. 3 Abstract Human risk assessment requires
More informationAnalysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data
The 2014 Cancer Program Annual Public Reporting of Outcomes/Annual Site Analysis Statistical Data from 2013 More than 70 percent of all newly diagnosed cancer patients are treated in the more than 1,500
More informationSmoking and misuse of certain pain medicines can affect the risk of developing renal cell cancer.
Renal cell cancer Renal cell cancer is a disease in which malignant (cancer) cells form in tubules of the kidney. Renal cell cancer (also called kidney cancer or renal adenocarcinoma) is a disease in which
More informationData Management & Analysis of the Focused Audits System
Focused Audits A novel approach to monitoring data quality in the central registry Cheryl Moody, BA, CTR California Cancer Reporting & Epidemiologic Surveillance (CalCARES) Program Institute for Population
More informationSurgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科
Surgical Management of Papillary Microcarcinoma 趙 子 傑 長 庚 紀 念 醫 院 林 口 總 院 一 般 外 科 Papillary microcarcinoma of thyroid Definition latent aberrant thyroid occult thyroid carcinoma latent papillary carcinoma)
More informationStephen R. Veach, M.D.
Stephen R. Veach, M.D. Memorial Sloan-Kettering Cancer Center International Oncology Programs 160 E. 53 rd Street New York, NY 10022 212-610 610-08780878 - tel 212-308 308-7063 - fax veachs@mskcc.org SCREENING
More informationPatient Guide. Brachytherapy: The precise answer for tackling breast cancer. Because life is for living
Patient Guide Brachytherapy: The precise answer for tackling breast cancer Because life is for living This booklet is designed to provide information that helps women who have been diagnosed with early
More informationOctober is Breast Cancer Awareness Month!
October is Breast Cancer Awareness Month! A STUDY OF CHARACTERISTICS AND MANAGEMENT OF BREAST CANCER IN TAIWAN Eric Kam-Chuan Lau, OMS II a, Jim Yu, OMSII a, Christabel Moy, OMSII a, Jian Ming Chen, MD
More informationReport with statistical data from 2007
2008 Cancer Program Annual Report with statistical data from 2007 Lake Cumberland Regional Hospital 305 Langdon Streett Somerset, KY 42503 Telephone: 606-679-7441 Fax: 606-678-9919 Cancer Committee Mullai,
More informationThe following information is only meant for people who have been diagnosed with advanced non-small cell
Important information for people with advanced non-small cell lung cancer The following information is only meant for people who have been diagnosed with advanced non-small cell lung cancer (NSCLC). NSCLC
More informationThe TV Series. www.healthybodyhealthymind.com INFORMATION TELEVISION NETWORK
The TV Series www.healthybodyhealthymind.com Produced By: INFORMATION TELEVISION NETWORK ONE PARK PLACE 621 NW 53RD ST BOCA RATON, FL 33428 1-800-INFO-ITV www.itvisus.com 2005 Information Television Network.
More informationVermont Facts. Prostate Cancer in Vermont. Vermont Cancer Registry Chronic Disease Epidemiology February 2010. Table of Contents:
Prostate Cancer in Vermont Vermont Cancer Registry Chronic Disease Epidemiology February 2010 Vermont Facts Incidence: Prostate cancer is the most commonly diagnosed cancer in men. Each year, approximately
More informationUnderstanding Your Diagnosis of Endometrial Cancer A STEP-BY-STEP GUIDE
Understanding Your Diagnosis of Endometrial Cancer A STEP-BY-STEP GUIDE Introduction This guide is designed to help you clarify and understand the decisions that need to be made about your care for the
More informationChapter 2 History of MD Anderson s Tumor Registry
Chapter 2 History of MD Anderson s Tumor Registry Sarah H. Taylor The Tumor Registry Department at The University of Texas MD Anderson Cancer Center is responsible for a database that contains demographic
More informationCHILDHOOD CANCER INCIDENCE UPDATE:
CHILDHOOD CANCER INCIDENCE UPDATE: A REVIEW AND ANALYSIS of CANCER REGISTRY DATA, 979, FOR DOVER TOWNSHIP (OCEAN COUNTY), NEW JERSEY Technical Report January Division of Epidemiology, Environmental and
More informationDuctal carcinoma in situ (DCIS)
DIAGNOSIS: DCIS Ductal carcinoma in situ (DCIS) This factsheet gives information on an early form of breast cancer called ductal carcinoma in situ (DCIS). It explains what it is, how your breast is made
More informationChapter 9. Quality and quality control
Chapter 9. Quality and quality control R.G. Skeet Herefordshire Health Authority, Victoria House, Hereford HR4 OAN, UK The cancer registry, above all else, is a source of information. Since it may be argued
More informationLung Cancer. Public Outcomes Report. Submitted by Omar A. Majid, MD
Public Outcomes Report Lung Cancer Submitted by Omar A. Majid, MD Lung cancer is the most common cancer-related cause of death among men and women. It has been estimated that there will be 226,1 new cases
More informationRadiation Therapy for Cancer Treatment
Radiation Therapy for Cancer Treatment Guest Expert: Kenneth, MD Associate Professor of Therapeutic Radiology www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center Answers with Dr. Ed and
More informationBreast Cancer. Sometimes cells keep dividing and growing without normal controls, causing an abnormal growth called a tumor.
Breast Cancer Introduction Cancer of the breast is the most common form of cancer that affects women but is no longer the leading cause of cancer deaths. About 1 out of 8 women are diagnosed with breast
More informationConversion to NAACCR 13
OCCR Oklahoma State Department of Health Oklahoma Central Cancer Registry NewsFlash January 2013 Winter Issue I NSIDE T HIS I SSUE 1 New OK CTRs 1 New OCCR Staff 2 Conversion to NAACCR 13 3 New Requirement
More information7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
More informationMETROPOLITAN LIFE INSURANCE COMPANY NEW YORK, NEW YORK
METROPOLITAN LIFE INSURANCE COMPANY NEW YORK, NEW YORK POLICYHOLDER: Your Employer Group Policy Form No: GPNP14-CI (Referred to as the Group Policy ) Certificate Form No: GCERT14-CI (Referred to as the
More informationBREAST CANCER AWARENESS FOR WOMEN AND MEN by Samar Ali A. Kader. Two years ago, I was working as a bedside nurse. One of my colleagues felt
Ali A. Kader, S. (2010). Breast cancer awareness for women and men. UCQ Nursing Journal of Academic Writing, Winter 2010, 70 76. BREAST CANCER AWARENESS FOR WOMEN AND MEN by Samar Ali A. Kader Two years
More informationOBJECTIVES By the end of this segment, the community participant will be able to:
Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway
More informationFrequently Asked Questions About Ovarian Cancer
Media Contact: Gerri Gomez Howard Cell: 303-748-3933 gerri@gomezhowardgroup.com Frequently Asked Questions About Ovarian Cancer What is ovarian cancer? Ovarian cancer is a cancer that forms in tissues
More informationChapter 13. The hospital-based cancer registry
Chapter 13. The hospital-based cancer registry J.L. Young California Tumor Registry, 1812 14th Street, Suite 200, Sacramento, CA 95814, USA Introduction The purposes of a hospital-based cancer registry
More informationLearning about Mouth Cancer
Learning about Mouth Cancer Creation of this material was made possible in part by a pioneering grant from CBCC-USA. Distributed by India Cancer Initiative What is mouth cancer? Our bodies are made up
More informationBreast Cancer Awareness Month
Aon Kenya Insurance Brokers Ltd Aon Hewitt Healthcare Division Breast Cancer Awareness Month Issue 12 October 2015 In this Issue 2 Cancer Statistics in Kenya 3 What is Breast Cancer? 4 Symptoms of Breast
More informationTHYROID CANCER. I. Introduction
THYROID CANCER I. Introduction There are over 11,000 new cases of thyroid cancer each year in the US. Females are more likely to have thyroid cancer than men by a ratio of 3:1, and it is more common in
More informationBreast Cancer Screening
Breast Cancer Screening The American Cancer Society and Congregational Health Ministry Team October Module To access this module via the Web, visit www.cancer.org and type in congregational health ministry
More informationAn Introduction to PROSTATE CANCER
An Introduction to PROSTATE CANCER Being diagnosed with prostate cancer can be a life-altering experience. It requires making some very difficult decisions about treatments that can affect not only the
More informationResearch Article Frequency of Surgery in Black Patients with Malignant Pleural Mesothelioma
Disease Markers Volume 2015, Article ID 282145, 5 pages http://dx.doi.org/10.1155/2015/282145 Research Article Frequency of Surgery in Black Patients with Malignant Pleural Mesothelioma Emanuela Taioli,
More informationLung Cancer in Vermont
Lung Cancer in Vermont Vermont Cancer Registry Chronic Disease Epidemiology November 2010 Vermont Facts Incidence: Lung cancer is the second most commonly diagnosed cancer in Vermont; approximately 260
More informationReport series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
More informationLifeProtect. Cancer Cover. For Intermediary Use Only
LifeProtect Cancer Cover For Intermediary Use Only There are few families in Ireland that have been unaffected by cancer. In fact, 1 in 3 men and 1 in 4 women in Ireland* will suffer from cancer at some
More informationFollow-Up Care for Breast Cancer
A Patient s Guide Follow-Up Care for Breast Cancer Recommendations of the American Society of Clinical Oncology The American Society of Clinical Oncology (ASCO) is a nonprofit organization which represents
More informationAccelerated Partial Breast Irradiation (APBI) for Breast Cancer [Preauthorization Required]
Accelerated Partial Breast Irradiation (APBI) for Breast Cancer [Preauthorization Required] Medical Policy: MP-SU-01-11 Original Effective Date: February 24, 2011 Reviewed: Revised: This policy applies
More informationOne out of every two men and one out of every three women will have some type of cancer at some point during their lifetime. 3
1. What is cancer? 2. What causes cancer?. What causes cancer? 3. Can cancer be prevented? The Facts One out of every two men and one out of every three women will have some type of cancer at some point
More informationTITLE: Comparison of the dosimetric planning of partial breast irradiation with and without the aid of 3D virtual reality simulation (VRS) software.
SAMPLE CLINICAL RESEARCH APPLICATION ABSTRACT: TITLE: Comparison of the dosimetric planning of partial breast irradiation with and without the aid of 3D virtual reality simulation (VRS) software. Hypothesis:
More informationTravel Distance to Healthcare Centers is Associated with Advanced Colon Cancer at Presentation
Travel Distance to Healthcare Centers is Associated with Advanced Colon Cancer at Presentation Yan Xing, MD, PhD, Ryaz B. Chagpar, MD, MS, Y Nancy You MD, MHSc, Yi Ju Chiang, MSPH, Barry W. Feig, MD, George
More informationThe current status of cancer care in Taiwan
The current status of cancer care in Taiwan Chien- Yuan Wu Director of Cancer Prevention and Control Division Health Promotion Administration Ministry of Health and Welfare, Taiwan Where is Taiwan? n Taiwan
More informationCancer insurance source list Aflac www.aflac.com 800-488-1771 or brokerrelations@aflac.com
Aflac www.aflac.com 800-488-1771 or brokerrelations@aflac.com Personal Cancer Indemnity and Maximum Difference Cancer All 3 18-70 for payroll; 18-64 for direct Benefits are paid directly to the policyholder,
More informationBreast Cancer. CSC Cancer Experience Registry Member, breast cancer
ESSENTIALS Breast Cancer Take things one step at a time. Try not to be overwhelmed by the tidal wave of technical information coming your way. Finally you know your body best; you have to be your own advocate.
More informationST JOSEPH REGIONAL HEALTH CENTER LUNG CANCER ANALYSIS Incidence, Diagnosis, Treatment and Survival
ST JOSEPH REGIONAL HEALTH CENTER LUNG CANCER ANALYSIS Incidence, Diagnosis, Treatment and Survival It is logical that the Cancer Program Committee choose to review the Lung Site, as Lung is the second
More informationUnderstanding INTRABEAM Intraoperative Radiation Therapy for Breast Cancer A patient guide
Understanding INTRABEAM Intraoperative Radiation Therapy for Breast Cancer A patient guide A diagnosis of breast cancer is never easy, but today there are more treatment options than ever before. A breast
More informationButler Memorial Hospital Community Health Needs Assessment 2013
Butler Memorial Hospital Community Health Needs Assessment 2013 Butler County best represents the community that Butler Memorial Hospital serves. Butler Memorial Hospital (BMH) has conducted community
More informationMale. Female. Death rates from lung cancer in USA
Male Female Death rates from lung cancer in USA Smoking represents an interesting combination of an entrenched industry and a clearly drug-induced cancer Tobacco Use in the US, 1900-2000 5000 100 Per Capita
More informationPediatric Oncology for Otolaryngologists
Pediatric Oncology for Otolaryngologists Frederick S. Huang, M.D. Division of Hematology/Oncology Department of Pediatrics The University of Texas Medical Branch Grand Rounds Presentation to Department
More informationThe American Cancer Society Cancer Prevention Study I: 12-Year Followup
Chapter 3 The American Cancer Society Cancer Prevention Study I: 12-Year Followup of 1 Million Men and Women David M. Burns, Thomas G. Shanks, Won Choi, Michael J. Thun, Clark W. Heath, Jr., and Lawrence
More information